drugset / Trial / NCT04992468

Dual Trigger for Elective Fertility Preservation

NCT04992468

Phase 4 Completed 136 enrolled Fundacion Dexeus
RandomizedParallel-groupOpen-labelTreatment

Summary

The widespread availability of efficient contraception as well as women's increased education has led to childbearing postponement. Combined with the increased recognition of the concept of "ovarian aging", this has opened the Pandora´s box of EOC, which is currently considered a safe and cost-efficient approach among assisted reproduction techniques. Previous studies have shown that two main factors determine the CLBR after EOC: 1) patient's age at the time of oocyte banking, and 2) the number of oocytes retrieved. Therefore, measures aiming at increasing the oocyte yield, specially the number of mature oocytes retrieved, will maximize the success of this technique. In the last few years, the dual trigger for final oocyte maturation has emerged has an approach that seems to improve both oocyte yield and quality when compared to the hCG trigger alone. Nowadays, the standard of care in EOC patients is final oocyte maturation with a single bolus of GnRH-a. Understanding the impact of the dual trigger on the number of MII oocytes retrieved in patients undergoing EOC will improve the treatment protocols and allow for a better patient counselling.

Timeline

Start
2021-10-05
Primary completion
2023-04-25
Completion
2023-04-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ovidrel Protein / enzyme biologic 250 ug
Background Gonal-f Protein / enzyme biologic 225 iu
Background Gonal-f Protein / enzyme biologic 300 iu
Background Progesterone Other / unclassified 200 mg
Background Triptorelin Other / unclassified 0.2 mg

Indications